Q2 2025 Covalon Technologies Ltd Earnings Call Transcript
Key Points
- Covalon Technologies Ltd (CVALF) reported strong revenue growth in its vascular access and surgical consumables and international sales channels, with both up more than 40% year-to-date compared to last year.
- The company has maintained a disciplined approach to spending, achieving its fifth consecutive quarter of profitability with positive adjusted EBIT.
- Covalon Technologies Ltd (CVALF) has a robust cash position with over $18 million in cash and zero debt, providing significant flexibility for growth and shareholder value initiatives.
- The company has successfully retained 100% of its top 50 US hospital customers, demonstrating the stickiness of its business and the quality of its products.
- Covalon Technologies Ltd (CVALF) has engaged Origin Merchant Partners to explore opportunities for mergers, acquisitions, and partnerships to maximize shareholder value and expand the reach of its technology.
- The company's gross margin was slightly lower this quarter due to a higher geographic mix of revenue from its international sales channel, which has a lower gross margin than the US sales channels.
- Covalon Technologies Ltd (CVALF) experienced a softer quarter in its US Advanced wound care sales channel, impacting overall revenue growth.
- The company has not yet executed a share buyback program, despite discussions with the board and Origin Merchant Partners.
- Covalon Technologies Ltd (CVALF) does not currently provide quarterly guidance, citing the stage of the company and the predictability of its revenue.
- The company's adjusted EBITDA for the trailing 12 months has decreased, attributed to the softer performance in the US Advanced wound care channel.
(technical difficulty)
Good morning ladies and gentlemen, and welcome to the Covalon's Q2 fiscal 2025 conference call and webcast. My name is Joel and I will be your conference operator today. As a reminder, today's conference is being recorded.
(Operator Instructions)
At this time, I would like to turn the conference over to Mr. Brent Ashton, Chief Executive Officer; Ms. Kim Crooks, Chief Operating Officer, and Ms. Katie Martinovich, interim Chief Financial Officer. Please go ahead, Mr. Ashton, Ms. Crooks, and Ms. Martinovich.
Hey, thank you so much, Joel, and good morning to all of you on the call today. I apologize for our technical difficulties at the start here. Thanks to some good quick troubleshooting by Saleha and other members of our team. We're back in business here. We do appreciate you connecting in today.
Kim Crooks, who's our newly promoted Chief Operating Officer, and Katie Martinovic, our interim Chief Financial Officer, who joined
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
